ValueScreener

ValueScreener company report

TuHURA Biosciences, Inc. (HURA)

NASDAQ / Healthcare / Biotechnology

Share price

1.83 USD Market dataClose of Oct 15, 2026

Market capitalisation

116.6M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Mar 31, 2026
Ratios computed
Oct 15, 2026
Filed years
14, FY2011 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-143.6% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

4.19x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

-31.6% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, as filed

FY2016 Net income: 8.9M USDFY2017 Net income: 8.1M USDFY2018 Net income: 11.1M USDFY2019 Net income: -8.0M USDFY2020 Net income: -9.1M USDFY2021 Net income: -38.3M USDFY2022 Net income: -22.7M USDFY2023 Revenue: 0.00 USDFY2023 Net income: -29.3M USDFY2024 Revenue: 0.00 USDFY2024 Net income: -21.7M USDFY2025 Revenue: 0.00 USDFY2025 Net income: -30.1M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -143.6% in FY2025, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Biotechnology industry (494 companies), -143.6% sits at the 26th percentile; the middle half of that group runs from -146.9% to -28.9%.

Is it safe

Current ratio was 0.78 in FY2025, in the band labelled "Short-term liabilities exceed short-term assets" (below 1.00), on lines anchored on Graham's defensive-investor criteria, suggesting short-term obligations above short-term assets.

Today, against the Biotechnology industry (556 companies), 0.78 sits at the 7th percentile; the middle half of that group runs from 2.39 to 9.18.

Year by year against peers
Whether TuHURA Biosciences, Inc.'s current ratio stayed above the median of the Biotechnology industry, year by year. (FY2023 to FY2025, 3 fiscal years of TuHURA Biosciences, Inc. with a comparable figure)
What could explain it
What in TuHURA Biosciences, Inc.'s filed statements could explain the movements. (3 readings drawn from the statement lines TuHURA Biosciences, Inc. filed)
What to check next
What to check next on TuHURA Biosciences, Inc., and where in its filings. (3 questions for TuHURA Biosciences, Inc.)
In one paragraph
One paragraph on TuHURA Biosciences, Inc.'s returns, cash, balance sheet and price. (4 of sixteen figures read for TuHURA Biosciences, Inc.)

These are HURA’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research HURAPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 31, 2026, accession 0001193125-26-134950.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

TuHURA Biosciences, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Return on equity-143.6% ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Return on capital employed, pre-tax
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Return on assets-109.9% ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Gross margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Operating margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Net margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

TuHURA Biosciences, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Current ratio0.78 ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Quick ratio0.78 ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Interest coverage
Why n/a

No operating income line is filed for this year.

n/a ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Altman Z-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Net debt
Why n/a

The FY2025 balance sheet carries no net debt we could read.

n/a ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Total assets 27.4MTotal liabilities 6.4MShareholders' equity 20.9MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What TuHURA Biosciences, Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 31, 2026, 0001193125-26-134950).

TuHURA Biosciences, Inc: balance sheet position
Total assets27.4M FiledFY2025 10-K, filed Mar 31, 2026
Total liabilities6.4M FiledFY2025 10-K, filed Mar 31, 2026
Shareholders' equity20.9M FiledFY2025 10-K, filed Mar 31, 2026
Cash3.6M FiledFY2025 10-K, filed Mar 31, 2026
Total debtn/a FiledFY2025 10-K, filed Mar 31, 2026
Net debtn/a
Current ratio0.78
Debt to equityn/a
  • Debt to equity: FY2025: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Interest cover: FY2025: No operating income line is filed for this year.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

TuHURA Biosciences, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
P/E on trailing twelve months0.02x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book4.19x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Price to sales
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Enterprise value to EBITDA
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Diluted earnings per share-0.63 USD FiledFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950

We publish no fair value or price target of our own. Value HURA on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for TuHURA Biosciences, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

TuHURA Biosciences, Inc: valuation
Share price1.83 USD
Market capitalisation116.6M USD
Enterprise value to EBITDAn/a
Graham numbern/m
Diluted earnings per share, FY2025-0.63 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Oct 3, 2016: low 0.00x, median 0.03x, high 0.25x, latest 0.02x. 1,091 trading days with a meaningful ratio, 1,431 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like TuHURA Biosciences, Inc

  1. Outlook Therapeutics, Inc. (OTLK)Market cap 121.7M USD
  2. NRx Pharmaceuticals, Inc. (NRXP)Market cap 117.3M USD
  3. Armata Pharmaceuticals, Inc. (ARMP)Market cap 114.9M USD
  4. Cibus, Inc. (CBUS)Market cap 98.6M USD
  5. Jyong Biotech Ltd. Ordinary Shares (MENS)Market cap 150.5M USD

Same industry (Biotechnology) and size band (Micro, 50M to 300M), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

TuHURA Biosciences, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield-31.6% ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Free cash flow-27.7M USD ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Free cash flow margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Dividend yield
Why n/a

The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
FY2016 Net income: 8.9M USDFY2017 Net income: 8.1M USDFY2018 Net income: 11.1M USDFY2019 Net income: -8.0M USDFY2020 Net income: -9.1M USDFY2021 Free cash flow: -18.9M USDFY2021 Net income: -38.3M USDFY2022 Free cash flow: -20.6M USDFY2022 Net income: -22.7M USDFY2023 Free cash flow: -12.0M USDFY2023 Net income: -29.3M USDFY2024 Free cash flow: -14.8M USDFY2024 Net income: -21.7M USDFY2025 Free cash flow: -27.7M USDFY2025 Net income: -30.1M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

TuHURA Biosciences, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
4.19xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
-31.6%FY2025Oct 15, 2026
n/aFY2025Mar 31, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
n/aFY2025Oct 15, 2026
n/a The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.
n/aFY2025Mar 31, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
0.78FY2025Mar 31, 2026
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Mar 31, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Mar 31, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 14 filed fiscal years on record, FY2011 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2016 to FY2025, read from the annual reports TuHURA Biosciences, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

TuHURA Biosciences, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY20250.00-29.4M-30.1M-0.63-27.7Mn/m-143.6%10-K, Mar 31, 20260001193125-26-134950
FY20240.00-17.5M-21.7M-1.21-14.8Mn/m-148.6%10-K, Mar 31, 20250000950170-25-047921
FY20230.0029.3M-29.3M-2.47-12.0Mn/mn/m10-K, Mar 31, 20250000950170-25-047921
FY2022n/an/a-22.7M-903.00-20.6Mn/a-192.1%10-K, Sep 27, 20220000950170-22-018865
FY2021n/an/a-38.3M-2800.00-18.9Mn/a-361.9%10-K, Sep 28, 20210001564590-21-049235
FY2020n/an/a-9.1M-1522.50n/an/a-3470.0%10-K, Sep 18, 20200001564590-20-044019
FY2019n/an/a-8.0M5530.00n/an/a-408.9%10-K, Sep 9, 20190001213900-19-017497
FY2018n/an/a11.1M9485.00n/an/a204.9%10-K, Sep 24, 20180001213900-18-012876
FY2017n/an/a8.1M12950.00n/an/a122.8%10-K, Sep 27, 20170001213900-17-010055
FY2016n/an/a8.9M14525.00n/an/a182.4%10-K, Sep 13, 20160001213900-16-016715
  • Revenue: Revenue was not positive in both 2023 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2021 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

TuHURA Biosciences, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Piotroski F-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 31, 2026, 0001193125-26-134950
Named tests met0 of 30 Computed
Beta1.49 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 19 not met, 11 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; High F-score, low P/B (Joseph Piotroski); High returns and growth; High yield, low payout; Dividends and buybacks; Low beta, profitable; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Cheapest quarter on P/B (David Dreman)
Not measured
Earnings yield and ROIC (Joel Greenblatt); Three forensic scores; Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; ROIC at or above WACC; P/E times P/B (Benjamin Graham); Cash-covered dividend; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(21)
  • Debt to Equity: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Piotroski F-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Return on Invested Capital: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Altman Z-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Beneish M-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Rev Growth 5Y: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Gross Margin: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Asset Turnover: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • EV/EBITDA: We do not hold this figure for this company, so there is nothing to show.
  • Interest Coverage: No operating income line is filed for this year.
  • Dividend Yield: The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • P/S Ratio: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 21 figures could not be read on this company, among them Debt to Equity, Piotroski F-Score, P/E Ratio. Each blank in the table above names the rest, with its reason. 11 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy